These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32360435)

  • 1. In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin.
    Danilov KA; Vassilieva SG; Polikarpova AV; Starikova AV; Shmidt AA; Galkin II; Tsitrina AA; Egorova TV; Orlov SN; Kotelevtsev YV
    Exp Cell Res; 2020 Jul; 392(2):112033. PubMed ID: 32360435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice.
    Bostick B; Yue Y; Lai Y; Long C; Li D; Duan D
    Hum Gene Ther; 2008 Aug; 19(8):851-6. PubMed ID: 18666839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
    Athanasopoulos T; Foster H; Foster K; Dickson G
    Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart.
    Yue Y; Li Z; Harper SQ; Davisson RL; Chamberlain JS; Duan D
    Circulation; 2003 Sep; 108(13):1626-32. PubMed ID: 12952841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
    Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
    Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
    Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress toward Gene Therapy for Duchenne Muscular Dystrophy.
    Chamberlain JR; Chamberlain JS
    Mol Ther; 2017 May; 25(5):1125-1131. PubMed ID: 28416280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy.
    Ho PP; Lahey LJ; Mourkioti F; Kraft PE; Filareto A; Brandt M; Magnusson KEG; Finn EE; Chamberlain JS; Robinson WH; Blau HM; Steinman L
    Proc Natl Acad Sci U S A; 2018 Sep; 115(39):E9182-E9191. PubMed ID: 30181272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
    Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
    J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice.
    Yue Y; Liu M; Duan D
    Mol Ther; 2006 Jul; 14(1):79-87. PubMed ID: 16563874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
    Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
    Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
    Koo T; Popplewell L; Athanasopoulos T; Dickson G
    Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles.
    Peccate C; Mollard A; Le Hir M; Julien L; McClorey G; Jarmin S; Le Heron A; Dickson G; Benkhelifa-Ziyyat S; Piétri-Rouxel F; Wood MJ; Voit T; Lorain S
    Hum Mol Genet; 2016 Aug; 25(16):3555-3563. PubMed ID: 27378686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer.
    Foster H; Sharp PS; Athanasopoulos T; Trollet C; Graham IR; Foster K; Wells DJ; Dickson G
    Mol Ther; 2008 Nov; 16(11):1825-32. PubMed ID: 18766174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
    Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
    Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.